All In Biotech

Drug Trial Radar · NCT02667886

Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma

A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Oct 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

74

Actual

Start

Apr 27, 2016

Primary completion

Apr 14, 2022

Study completion Apr 14, 2022

Sponsor

Lead sponsor
X4 PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jan 29, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to test different doses of X4P-001 given alone and in combination with axitinib in participants diagnosed with advanced renal cell carcinoma. The goals of the study are to determine the safety and tolerability of X4P-001, as well as the potential effect it may have on the body and the cancer tumor.

Conditions

  • Clear Cell Renal Cell Carcinoma

Interventions

  • X4P-001Drug

    Continuous, oral dosing

  • axitinibDrug

    Continuous, oral dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose of study drug up to 10 days after last dosing (maximum exposure: 52.1 months)

Locations

20 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Jacksonville, Florida

  • Site not named

    Chicago, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Iowa City, Iowa

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Boston, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Saint Paul, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    Hackensack, New Jersey

  • Site not named

    New York, New York

  • Site not named

    The Bronx, New York

  • Site not named

    Toledo, Ohio

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Greenville, South Carolina

  • Site not named

    Houston, Texas

  • Site not named

    Gyeyang-gu, Seoul, South Korea

  • Site not named

    Seongdu, Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.